**
In a troubling revelation, internal records have surfaced detailing a meeting between top officials from the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson, that raises serious questions about the influence of corporate interests on public health policy. This June 2025 gathering occurred as Bayer faced a torrent of lawsuits from individuals claiming that its glyphosate-based herbicides, such as Roundup, caused cancer, sparking concerns over the integrity of regulatory processes.
Corporate Interests at the Forefront
The meeting, held on June 17, involved key EPA figures, including Lee Zeldin, the agency’s administrator, and Nancy Beck, a former senior director at the American Chemistry Council now serving as the EPA’s principal deputy assistant administrator. The discussions reportedly centred on “litigation” matters, including the potential for Supreme Court involvement in Bayer’s ongoing legal battles. These lawsuits, filed by thousands of plaintiffs, allege that Bayer neglected to inform users about the cancer risks associated with its products, a claim supported by numerous studies over the years.
Bayer’s strategy to mitigate its legal troubles hinges on a pivotal argument: if the EPA does not mandate a cancer warning for its glyphosate products, the company should not be held accountable for failing to provide such a warning. While one appellate court has sided with Bayer, many others have dismissed this defence, including the Biden administration’s solicitor general. The Trump administration, however, has actively defended Bayer’s position, further entrenching the company’s influence within the regulatory landscape.
A Pattern of Regulatory Capture
Bayer has characterised the June meeting as a standard part of the regulatory process, asserting that it has been transparent regarding its litigation stance. However, critics argue that the meeting underscores a troubling trend where corporate leaders wield significant power over regulatory agencies, potentially compromising the health and safety of the public. Nathan Donley, environmental health science director at the Centre for Biological Diversity, expressed concern over the prioritisation of corporate profits over citizen health, highlighting the alarming implications of such high-level interactions.
This meeting is not an isolated incident; since it took place, the Trump administration has taken several steps that appear to favour Bayer. Notably, on December 1, 2025, the solicitor general, appointed by Trump, urged the Supreme Court to hear Bayer’s case. This was followed by the invocation of the Defense Production Act in February 2026, aimed at safeguarding glyphosate production and providing legal protections for manufacturers like Bayer. Most recently, in March, the administration filed an amicus brief supporting Bayer in the Supreme Court, further solidifying its backing.
The Call for Greater Transparency
Legal experts and advocates are raising alarms over the implications of such meetings. Whitney Di Bona, an attorney and consumer safety advocate, expressed disquiet that Bayer’s CEO could engage directly with the EPA to discuss limiting the company’s liability while victims of glyphosate exposure seem to have been sidelined in the conversation. The disparity in access to regulatory officials highlights a systemic issue where industry leaders enjoy a privileged position, while ordinary citizens and those affected by harmful products struggle to have their voices heard.
Naomi Oreskes, a professor at Harvard, echoed these sentiments, suggesting that this pattern of corporate access to government officials is detrimental to public interest. Furthermore, Zen Honeycutt, founder of Moms Across America, noted that the coercive tactics of chemical companies towards regulatory bodies are not new. Despite her organisation’s efforts to engage with the EPA regarding pesticide restrictions, she lamented the lack of substantive action, illustrating a disconnect between corporate lobbying and genuine public health advocacy.
Why it Matters
The revelations surrounding Bayer’s interactions with the Trump administration illuminate a concerning reality: the regulatory processes designed to protect public health can be unduly influenced by powerful corporate interests. As the legal battles over glyphosate continue, it is imperative that we scrutinise the integrity of our regulatory institutions and demand accountability from those in power. The health of millions hangs in the balance, and it is essential that the voices of affected individuals are prioritised over corporate profit margins. This situation serves as a stark reminder of the need for transparency and reform within our regulatory frameworks to ensure that public health remains at the forefront of policy decisions.
